Multimodal management - of value in fulminant acute pancreatitis?

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Multiple organ dysfunction syndrome (MODS) is a primary driver of mortality in acute pancreatitis.
• Current treatments for MODS in acute pancreatitis are limited to organ support, lacking targeted therapies for underlying mechanisms.

Purpose of the Study:

• To assess the efficacy of a platelet-activating factor inhibitor (PAFI), a monoclonal antibody against platelet endothelial cell adhesion molecule 1 (PECAM-1-MAb), and N-acetylcysteine (NAC) in mitigating organ dysfunction in experimental acute pancreatitis.
• To evaluate the effects of these agents individually and in combination.

Main Methods:

• Severe acute pancreatitis was induced in rats using taurodeoxycholate.
• Therapeutic interventions were administered 1 or 3 hours post-induction, with evaluations conducted 6 hours after induction.
• Endothelial integrity, assessed via the endothelial barrier leakage index, was the primary measure of organ dysfunction.

Main Results:

• Acute pancreatitis significantly compromised endothelial integrity across multiple organs and reduced protease inhibitor levels.
• All tested treatment modalities, regardless of administration timing, demonstrated significant amelioration of endothelial barrier impairment.
• Combined treatment with NAC and PECAM-1-MAb, or PECAM-1-MAb and PAFI, was most effective, restoring endothelial barrier integrity to normal levels in most organs.

Conclusions:

• Combination therapy involving N-acetylcysteine (NAC), PECAM-1-MAb, and/or PAFI presents a potential causative-directed therapeutic strategy for MODS in severe acute pancreatitis.
• These novel therapeutic combinations may serve as valuable adjuncts to existing organ-supportive care for MODS.